Symbols / OKYO Stock $1.62 +0.00% OKYO Pharma Limited
OKYO (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Ratings
Current target
$1.62
Low
$7.00
High
$13.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | init | Piper Sandler | — → Overweight | $7 |
| 2025-12-08 | init | B. Riley Securities | — → Buy | $5 |
| 2025-09-23 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-05-05 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-10-16 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-03-22 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-01-08 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-12-05 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-02 | init | HC Wainwright & Co. | — → Buy | $4 |
- Denver eye meetings put OKYO’s CEO and eye-pain drug study on stage - Stock Titan Wed, 29 Apr 2026 07
- OKYO Pharma Announces Chairman and Founder Acquires Shares - Yahoo Finance Mon, 15 Dec 2025 08
- Number of shareholders of OKYO Pharma Limited – NASDAQ:OKYO - TradingView Mon, 11 May 2026 03
- OKYO Pharma stock tumbles on $20 million public offering announcement - Investing.com Fri, 13 Feb 2026 08
- OKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in Denver - TipRanks Wed, 29 Apr 2026 07
- OKYO Earnings History & Surprises | EPS & Revenue Results | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill hu, 19 Mar 2026 22
- OKYO Pharma Limited Transitions ATM Equity Offering to Leerink Partners LLC for Enhanced Capital Access - Quiver Quantitative Wed, 11 Feb 2026 08
- OKYO Pharma Ltd Rings the Opening Bell - Nasdaq Fri, 19 Dec 2025 08
- Individual investors invested in OKYO Pharma Limited (NASDAQ:OKYO) up 16% last week, insiders too were rewarded - simplywall.st Fri, 31 Oct 2025 07
- OKYO Pharma (NASDAQ: OKYO) showcases urcosimod NCP data at Eyecelerator and ARVO - Stock Titan Wed, 29 Apr 2026 07
- OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - Yahoo Finance hu, 12 Feb 2026 08
- H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target - Investing.com ue, 06 Jan 2026 08
- OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting - TipRanks ue, 07 Apr 2026 07
- Eye pain drug data gets ASCRS spotlight ahead of OKYO's next trial - Stock Titan ue, 07 Apr 2026 07
- OKYO Pharma to hold advisory board meeting at ASCRS conference - Investing.com ue, 07 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
7.09
-54.97%
|
15.75
+19.43%
|
13.19
+112.10%
|
6.22
|
| Research And Development |
|
2.25
-72.65%
|
8.24
+30.07%
|
6.34
+293.75%
|
1.61
|
| Other Operating Expenses |
|
4.84
-35.55%
|
7.51
+9.59%
|
6.85
+48.64%
|
4.61
|
| Total Expenses |
|
7.09
-54.97%
|
15.75
+19.43%
|
13.19
+112.10%
|
6.22
|
| Operating Income |
|
-7.09
+54.97%
|
-15.75
-19.43%
|
-13.19
-112.10%
|
-6.22
|
| EBITDA |
|
-7.10
+54.93%
|
-15.75
-19.44%
|
-13.18
-112.11%
|
-6.22
|
| Normalized EBITDA |
|
-7.10
+54.93%
|
-15.75
-19.44%
|
-13.18
-112.11%
|
-6.22
|
| Reconciled Depreciation |
|
0.00
-33.70%
|
0.00
+1.82%
|
0.00
+62.89%
|
0.00
|
| EBIT |
|
-7.10
+54.92%
|
-15.75
-19.43%
|
-13.19
-112.10%
|
-6.22
|
| Total Unusual Items |
|
—
|
—
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.00
|
0.00
|
| Special Income Charges |
|
—
|
—
|
0.00
|
0.00
|
| Write Off |
|
—
|
—
|
0.00
|
0.00
|
| Net Income |
|
-4.71
+72.03%
|
-16.83
-26.78%
|
-13.27
-144.37%
|
-5.43
|
| Pretax Income |
|
-7.97
+52.57%
|
-16.80
-26.49%
|
-13.28
-113.65%
|
-6.22
|
| Net Non Operating Interest Income Expense |
|
-0.88
+16.63%
|
-1.05
-989.40%
|
-0.10
|
0.00
|
| Interest Expense Non Operating |
|
0.87
-17.38%
|
1.05
+989.40%
|
0.10
|
0.00
|
| Net Interest Income |
|
-0.88
+16.63%
|
-1.05
-989.40%
|
-0.10
|
0.00
|
| Interest Expense |
|
0.87
-17.38%
|
1.05
+989.40%
|
0.10
|
0.00
|
| Interest Income Non Operating |
|
0.01
|
0.00
|
0.00
|
0.00
|
| Interest Income |
|
0.01
|
0.00
|
0.00
|
0.00
|
| Tax Provision |
|
-3.26
-14660.04%
|
0.02
+283.71%
|
-0.01
+98.45%
|
-0.79
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+27103.48%
|
0.00
-99.27%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-4.71
+72.03%
|
-16.83
-26.78%
|
-13.27
-144.37%
|
-5.43
|
| Net Income From Continuing Operation Net Minority Interest |
|
-4.71
+72.03%
|
-16.83
-26.78%
|
-13.27
-144.37%
|
-5.43
|
| Net Income From Continuing And Discontinued Operation |
|
-4.71
+72.03%
|
-16.83
-26.78%
|
-13.27
-144.37%
|
-5.43
|
| Net Income Continuous Operations |
|
-4.71
+72.03%
|
-16.83
-26.78%
|
-13.27
-144.37%
|
-5.43
|
| Normalized Income |
|
-4.71
+72.03%
|
-16.83
-26.78%
|
-13.27
-144.37%
|
-5.43
|
| Net Income Common Stockholders |
|
-4.71
+72.03%
|
-16.83
-26.78%
|
-13.27
-144.37%
|
-5.43
|
| Diluted EPS |
|
-0.12
+79.09%
|
-0.57
+6.56%
|
-0.61
-69.44%
|
-0.36
|
| Basic EPS |
|
-0.12
+79.09%
|
-0.57
+6.56%
|
-0.61
-69.44%
|
-0.36
|
| Basic Average Shares |
|
39.49
+34.57%
|
29.34
+31.84%
|
22.26
+47.74%
|
15.06
|
| Diluted Average Shares |
|
39.49
+34.57%
|
29.34
+31.84%
|
22.26
-97.21%
|
798.26
|
| Diluted NI Availto Com Stockholders |
|
-4.71
+72.03%
|
-16.83
-26.78%
|
-13.27
-144.37%
|
-5.43
|
| Total Other Finance Cost |
|
0.01
|
—
|
—
|
—
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets |
|
3.68
+138.59%
|
1.54
-70.38%
|
5.20
+21.00%
|
4.30
|
| Current Assets |
|
3.68
+138.98%
|
1.54
-70.41%
|
5.20
+20.98%
|
4.30
|
| Cash Cash Equivalents And Short Term Investments |
|
1.56
+88.78%
|
0.83
-79.56%
|
4.05
+49.79%
|
2.70
|
| Cash And Cash Equivalents |
|
1.56
+88.78%
|
0.83
-79.56%
|
4.05
+49.79%
|
2.70
|
| Cash Financial |
|
1.56
+88.78%
|
0.83
-79.56%
|
4.05
+49.79%
|
2.70
|
| Receivables |
|
1.89
+225.17%
|
0.58
-40.72%
|
0.98
+10.94%
|
0.88
|
| Other Receivables |
|
0.00
-19.43%
|
0.01
-98.36%
|
0.34
+1681.75%
|
0.02
|
| Taxes Receivable |
|
1.88
+227.54%
|
0.58
-9.99%
|
0.64
-26.04%
|
0.86
|
| Prepaid Assets |
|
0.23
+73.19%
|
0.13
-24.01%
|
0.17
-75.92%
|
0.71
|
| Total Non Current Assets |
|
0.00
-39.25%
|
0.00
-53.58%
|
0.01
+38.11%
|
0.01
|
| Net PPE |
|
0.00
-39.25%
|
0.00
-53.58%
|
0.01
+38.11%
|
0.01
|
| Gross PPE |
|
0.01
+0.32%
|
0.01
-31.66%
|
0.02
+56.61%
|
0.01
|
| Accumulated Depreciation |
|
-0.01
-18.94%
|
-0.01
+12.12%
|
-0.01
-77.84%
|
-0.00
|
| Properties |
|
—
|
—
|
—
|
0.00
|
| Machinery Furniture Equipment |
|
0.01
+0.32%
|
0.01
-31.66%
|
0.02
+56.61%
|
0.01
|
| Total Liabilities Net Minority Interest |
|
9.23
+24.34%
|
7.42
+2.26%
|
7.26
+436.30%
|
1.35
|
| Current Liabilities |
|
9.23
+24.34%
|
7.42
+2.26%
|
7.26
+436.30%
|
1.35
|
| Payables And Accrued Expenses |
|
9.23
+24.34%
|
7.42
+47.18%
|
5.04
+272.60%
|
1.35
|
| Payables |
|
8.85
+34.26%
|
6.59
+108.11%
|
3.17
+301.47%
|
0.79
|
| Accounts Payable |
|
7.90
+28.91%
|
6.13
+164.76%
|
2.31
+212.02%
|
0.74
|
| Other Payable |
|
0.09
-14.28%
|
0.10
+41.85%
|
0.07
|
—
|
| Current Accrued Expenses |
|
0.38
-54.40%
|
0.83
-55.73%
|
1.88
+232.26%
|
0.56
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
2.22
|
—
|
| Current Debt |
|
—
|
—
|
2.22
|
—
|
| Other Current Borrowings |
|
—
|
—
|
2.22
|
—
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.00
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
—
|
0.00
|
| Stockholders Equity |
|
-5.55
+5.61%
|
-5.88
-186.36%
|
-2.05
-169.66%
|
2.95
|
| Common Stock Equity |
|
-5.55
+5.61%
|
-5.88
-186.36%
|
-2.05
-169.66%
|
2.95
|
| Capital Stock |
|
146.72
+2.52%
|
143.11
+8.93%
|
131.39
+5.98%
|
123.98
|
| Common Stock |
|
146.72
+2.52%
|
143.11
+8.93%
|
131.39
+5.98%
|
123.98
|
| Share Issued |
|
36.02
+8.05%
|
33.34
-34.69%
|
51.04
+141.38%
|
21.14
|
| Ordinary Shares Number |
|
36.02
+8.05%
|
33.34
-34.69%
|
51.04
+141.38%
|
21.14
|
| Retained Earnings |
|
-143.02
-0.35%
|
-142.52
-13.39%
|
-125.70
-11.80%
|
-112.43
|
| Gains Losses Not Affecting Retained Earnings |
|
-11.47
-1.41%
|
-11.31
+1.23%
|
-11.45
-4.01%
|
-11.01
|
| Total Equity Gross Minority Interest |
|
-5.55
+5.61%
|
-5.88
-186.36%
|
-2.05
-169.66%
|
2.95
|
| Total Capitalization |
|
-5.55
+5.61%
|
-5.88
-186.36%
|
-2.05
-169.66%
|
2.95
|
| Working Capital |
|
-5.55
+5.63%
|
-5.88
-185.52%
|
-2.06
-170.03%
|
2.94
|
| Invested Capital |
|
-5.55
+5.61%
|
-5.88
-3732.20%
|
0.16
-94.51%
|
2.95
|
| Total Debt |
|
—
|
—
|
2.22
|
0.00
|
| Capital Lease Obligations |
|
—
|
—
|
—
|
0.00
|
| Net Tangible Assets |
|
-5.55
+5.61%
|
-5.88
-186.36%
|
-2.05
-169.66%
|
2.95
|
| Tangible Book Value |
|
-5.55
+5.61%
|
-5.88
-186.36%
|
-2.05
-169.66%
|
2.95
|
| Duefrom Related Parties Current |
|
—
|
—
|
—
|
0.00
|
| Dueto Related Parties Current |
|
0.86
+139.56%
|
0.36
-53.96%
|
0.78
+1556.41%
|
0.05
|
| Foreign Currency Translation Adjustments |
|
-11.47
-1.41%
|
-11.31
+1.23%
|
-11.45
-4.01%
|
-11.01
|
| Other Equity Interest |
|
2.23
-53.98%
|
4.84
+30.48%
|
3.71
+54.09%
|
2.41
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-1.81
+80.92%
|
-9.49
-23.33%
|
-7.70
-40.73%
|
-5.47
|
| Cash Flow From Continuing Operating Activities |
|
-1.81
+80.92%
|
-9.49
-23.33%
|
-7.70
-40.73%
|
-5.47
|
| Net Income From Continuing Operations |
|
-7.97
+52.57%
|
-16.80
-26.49%
|
-13.28
-113.65%
|
-6.22
|
| Depreciation Amortization Depletion |
|
0.00
-33.70%
|
0.00
+1.82%
|
0.00
+62.89%
|
0.00
|
| Depreciation |
|
0.00
-33.70%
|
0.00
+1.82%
|
0.00
+62.89%
|
0.00
|
| Depreciation And Amortization |
|
0.00
-33.70%
|
0.00
+1.82%
|
0.00
+62.89%
|
0.00
|
| Other Non Cash Items |
|
1.99
-42.62%
|
3.46
+2912.53%
|
0.11
+86.31%
|
0.06
|
| Stock Based Compensation |
|
0.73
-34.45%
|
1.12
-12.82%
|
1.29
-25.99%
|
1.74
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
|
0.00
|
| Operating Gains Losses |
|
-0.19
-455.74%
|
0.05
+38.64%
|
0.04
+235.79%
|
-0.03
|
| Gain Loss On Investment Securities |
|
-0.09
-6544.40%
|
-0.00
+88.57%
|
-0.01
+35.18%
|
-0.02
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.10
-275.74%
|
0.06
+7.80%
|
0.05
+654.63%
|
-0.01
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Change In Working Capital |
|
1.63
-39.06%
|
2.67
-32.35%
|
3.95
+485.38%
|
-1.02
|
| Change In Receivables |
|
—
|
0.00
-100.00%
|
0.17
+512.65%
|
0.03
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
0.03
|
| Change In Payables And Accrued Expense |
|
1.72
-22.97%
|
2.23
-41.00%
|
3.78
+1616.75%
|
-0.25
|
| Change In Payable |
|
1.72
-22.97%
|
2.23
-41.00%
|
3.78
+1616.75%
|
-0.25
|
| Change In Account Payable |
|
1.22
-56.54%
|
2.80
-5.55%
|
2.96
+1094.58%
|
-0.30
|
| Change In Other Current Assets |
|
-0.09
-120.53%
|
0.44
+162.50%
|
0.17
+120.91%
|
-0.80
|
| Investing Cash Flow |
|
-0.00
|
0.00
+100.00%
|
-0.01
-254.46%
|
-0.00
|
| Cash Flow From Continuing Investing Activities |
|
-0.00
|
0.00
+100.00%
|
-0.01
-254.46%
|
-0.00
|
| Net PPE Purchase And Sale |
|
-0.00
|
0.00
+100.00%
|
-0.01
-254.46%
|
-0.00
|
| Purchase Of PPE |
|
-0.00
|
0.00
+100.00%
|
-0.01
-254.46%
|
-0.00
|
| Capital Expenditure |
|
-0.00
|
—
|
-0.01
-254.46%
|
-0.00
|
| Financing Cash Flow |
|
2.66
-57.22%
|
6.21
-33.41%
|
9.32
+332.99%
|
2.15
|
| Cash Flow From Continuing Financing Activities |
|
2.66
-57.22%
|
6.21
-33.41%
|
9.32
+332.99%
|
2.15
|
| Net Issuance Payments Of Debt |
|
0.95
|
0.00
-100.00%
|
2.00
|
0.00
|
| Issuance Of Debt |
|
0.95
|
0.00
-100.00%
|
2.00
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
|
0.00
|
0.00
|
| Short Term Debt Issuance |
|
0.95
|
0.00
-100.00%
|
2.00
|
0.00
|
| Net Short Term Debt Issuance |
|
0.95
|
0.00
-100.00%
|
2.00
|
0.00
|
| Net Common Stock Issuance |
|
1.71
-72.53%
|
6.21
-15.22%
|
7.32
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
|
0.00
-100.00%
|
2.15
|
| Changes In Cash |
|
0.84
+125.70%
|
-3.28
-302.32%
|
1.62
+148.91%
|
-3.32
|
| Effect Of Exchange Rate Changes |
|
-0.11
-272.53%
|
0.06
+122.88%
|
-0.28
+68.18%
|
-0.87
|
| Beginning Cash Position |
|
0.83
-79.56%
|
4.05
+49.79%
|
2.70
-60.80%
|
6.89
|
| End Cash Position |
|
1.56
+88.78%
|
0.83
-79.56%
|
4.05
+49.79%
|
2.70
|
| Free Cash Flow |
|
-1.81
+80.91%
|
-9.49
-23.24%
|
-7.70
-40.80%
|
-5.47
|
| Common Stock Issuance |
|
1.71
-72.53%
|
6.21
-15.22%
|
7.32
|
0.00
|
| Issuance Of Capital Stock |
|
1.71
-72.53%
|
6.21
-15.22%
|
7.32
|
0.00
|
| Taxes Refund Paid |
|
2.00
|
0.00
-100.00%
|
0.20
|
0.00
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|